These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 26021076)

  • 21. Development of vaccines for prevention of Ebola virus infection.
    Ye L; Yang C
    Microbes Infect; 2015 Feb; 17(2):98-108. PubMed ID: 25526819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates.
    Pyankov OV; Bodnev SA; Pyankova OG; Solodkyi VV; Pyankov SA; Setoh YX; Volchkova VA; Suhrbier A; Volchkov VV; Agafonov AA; Khromykh AA
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S368-71. PubMed ID: 25732811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ebolavirus Vaccines: Progress in the Fight Against Ebola Virus Disease.
    Wu XX; Yao HP; Wu NP; Gao HN; Wu HB; Jin CZ; Lu XY; Xie TS; Li LJ
    Cell Physiol Biochem; 2015; 37(5):1641-58. PubMed ID: 26535889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Designing Efficacious Vesicular Stomatitis Virus-Vectored Vaccines Against Ebola Virus.
    Wong G; Qiu X
    Methods Mol Biol; 2016; 1403():245-57. PubMed ID: 27076134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A single phosphorodiamidate morpholino oligomer targeting VP24 protects rhesus monkeys against lethal Ebola virus infection.
    Warren TK; Whitehouse CA; Wells J; Welch L; Heald AE; Charleston JS; Sazani P; Reid SP; Iversen PL; Bavari S
    mBio; 2015 Feb; 6(1):. PubMed ID: 25670780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. VSVΔG/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection.
    Williams KJ; Qiu X; Fernando L; Jones SM; Alimonti JB
    Viral Immunol; 2015 Feb; 28(1):51-61. PubMed ID: 25494457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progress in Elucidating Potential Markers and Mechanisms of Rapid Protection Conferred by the VSV-Vectored Ebola Virus Vaccine.
    Wong G
    mBio; 2019 Jul; 10(4):. PubMed ID: 31311887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thermostable Ebola virus vaccine formulations lyophilized in the presence of aluminum hydroxide.
    Chisholm CF; Kang TJ; Dong M; Lewis K; Namekar M; Lehrer AT; Randolph TW
    Eur J Pharm Biopharm; 2019 Mar; 136():213-220. PubMed ID: 30703544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.
    Warfield KL; Swenson DL; Olinger GG; Kalina WV; Aman MJ; Bavari S
    J Infect Dis; 2007 Nov; 196 Suppl 2():S430-7. PubMed ID: 17940980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals.
    Wong G; Richardson JS; Cutts T; Qiu X; Kobinger GP
    Antiviral Res; 2015 Apr; 116():17-9. PubMed ID: 25596432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge.
    Marzi A; Reynolds P; Mercado-Hernandez R; Callison J; Feldmann F; Rosenke R; Thomas T; Scott DP; Hanley PW; Haddock E; Feldmann H
    EBioMedicine; 2019 Nov; 49():223-231. PubMed ID: 31631035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
    Mire CE; Matassov D; Geisbert JB; Latham TE; Agans KN; Xu R; Ota-Setlik A; Egan MA; Fenton KA; Clarke DK; Eldridge JH; Geisbert TW
    Nature; 2015 Apr; 520(7549):688-691. PubMed ID: 25853476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.
    Bengtsson KL; Song H; Stertman L; Liu Y; Flyer DC; Massare MJ; Xu RH; Zhou B; Lu H; Kwilas SA; Hahn TJ; Kpamegan E; Hooper J; Carrion R; Glenn G; Smith G
    Vaccine; 2016 Apr; 34(16):1927-35. PubMed ID: 26921779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ebola vaccines in clinical trial: The promising candidates.
    Wang Y; Li J; Hu Y; Liang Q; Wei M; Zhu F
    Hum Vaccin Immunother; 2017 Jan; 13(1):153-168. PubMed ID: 27764560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans.
    Vu H; Shulenin S; Grolla A; Audet J; He S; Kobinger G; Unfer RC; Warfield KL; Aman MJ; Holtsberg FW
    Antiviral Res; 2016 Feb; 126():55-61. PubMed ID: 26681387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant subunit vaccines protect guinea pigs from lethal Ebola virus challenge.
    Lehrer AT; Wong TS; Lieberman MM; Johns L; Medina L; Feldmann F; Feldmann H; Marzi A
    Vaccine; 2019 Nov; 37(47):6942-6950. PubMed ID: 31324500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccines against 'the other' Ebolavirus species.
    Kozak RA; Kobinger GP
    Expert Rev Vaccines; 2016 Sep; 15(9):1093-100. PubMed ID: 27010528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?
    Meyer M; Malherbe DC; Bukreyev A
    Trends Microbiol; 2019 Jan; 27(1):8-16. PubMed ID: 30201511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review of Ebola virus infections in domestic animals.
    Weingartl HM; Nfon C; Kobinger G
    Dev Biol (Basel); 2013; 135():211-8. PubMed ID: 23689899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Strategies against Ebola Virus Infection.
    Liu CH; Hu YT; Wong SH; Lin LT
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35336986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.